
UCB to acquire IMIDomics’ Patient Insight Business
Global pharmaceutical company UCB has acquired the Patient Insights Business of IMIDomics, giving it access to a large, multi-omics dataset for immunology studies. IMIDomics’ Patient Insight Business includes over 18 years of clinical and molecular data generation. It integrates epidemiological information, clinical histories, imaging data, multi-omic profiles, and longitudinal patient samples. … Read More












